When it comes to breakthrough therapies, sometimes it seems as though each new potentially life-saving drug comes with a price tag more expensive than the last. Novartis’ Kymriah, which became the first to win FDA approval for a groundbreaking new type of cancer treatment called CAR-T last year, priced its therapy at $475,000. A gene therapy from Spark Therepeutics approved in December to treat a rare, inherited form of blindness became the expensive medicine in the U.S.